Mon Health Cancer Center Expands Treatment Options in the Fight Against Advanced Prostate Cancer
Posted Date: 5/18/2023
Mon Health Cancer Center today announced that it has been trained and certified by Dendreon Pharmaceuticals to offer PROVENGE ® (sipuleucel-T) treatment through the Dendreon Service-Ready program. Mon Health Cancer Center is excited to offer to its patients the only FDA-approved cellular immunotherapy for the treatment of advanced prostate cancer.
Mon Health Cancer Center joins the network of the more than 2,400 treatment centers that have qualified as Dendreon Service-Ready practices and offered PROVENGE since the treatment was first approved by the FDA in 2010.
“Mon Health Cancer Center is proud to make PROVENGE available to our patients. As one of the most commonly diagnosed cancers and the second leading cause of death in men in the US, prostate cancer poses a significant threat to the lives of men worldwide,” said David Goldberg, President and CEO of Mon Health System and Executive Vice President of Vandalia Health. “Providing our patients with another treatment option to fight prostate cancer is of utmost importance. Being able to provide PROVENGE treatment furthers our commitment to men’s health and the prostate cancer community.”
PROVENGE is a custom-made immunotherapy that trains the body’s immune system to seek out and attack prostate cancer cells, helping patients personalize their fight against advanced prostate cancer and has been proven to extend life for certain men with metastatic castrate-resistant prostate cancer.
“By offering this personalized, innovative immunotherapy, we are taking significant strides towards improving access to treatment options for those battling advanced prostate cancer,” said
Dr. Ihtishaam Qazi, Oncologist at Mon Health Cancer Center.
In the clinical study that supports its FDA approval, men treated with PROVENGE had a 22.5% reduced risk of death than those not treated with PROVENGE. Most side effects of PROVENGE were generally mild to moderate and well-tolerated. The most common side effects in clinical studies were chills, fatigue, fever, back pain, nausea, joint ache, and headache, and 1.5% of men discontinued treatment with PROVENGE due to side effects.
“We are pleased to add Mon Health Cancer Center to our growing network of practices providing PROVENGE therapy to patients and to be able to offer another treatment option for patients in this community with advanced prostate cancer,” said Clay Godwin, VP-Sales, Marketing, Reimbursement, and Market Access at Dendreon.
*Individual results may vary.
Popularity:
This record has been viewed 1972 times.